Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : XLO save search
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-04-01 (Crawled : 20:00) - globenewswire.com
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.08%
H: 0.04%
C: -1.0%
business year pipeline therapeutics financial results
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
Published: 2024-03-28 (Crawled : 11:00) - globenewswire.com
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: 200.47%
H: 0.52%
C: -43.75%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.33%
H: 0.85%
C: 0.0%
million therapeutics
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Published: 2024-03-28 (Crawled : 11:00) - globenewswire.com
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: 200.47%
H: 0.52%
C: -43.75%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.33%
H: 0.85%
C: 0.0%
il-12 license program agreement
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 17.98%
C: 7.42%
conference health care therapeutics
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
Published: 2024-01-31 (Crawled : 21:00) - globenewswire.com
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: 2.22%
H: 4.92%
C: 0.84%
conference therapeutics
CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market to grow by USD 2.23 billion between 2023 and 2028, growth Driven by High target affinity and specificity of CTLA4 inhibitors - Technavio
Published: 2024-01-26 (Crawled : 02:00) - prnewswire.com
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: 4.69%
H: 4.55%
C: -2.99%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 2.92%
H: 1.06%
C: -3.05%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: -1.35%
H: 0.12%
C: -0.83%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 1.07%
H: 0.1%
C: -0.94%
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: 3.13%
H: 11.02%
C: 7.11%
protein growth market
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
Published: 2024-01-08 (Crawled : 12:30) - globenewswire.com
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: -2.33%
H: 3.19%
C: 2.38%
xtx301 pipeline therapeutics promise
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
Published: 2023-12-07 (Crawled : 12:30) - globenewswire.com
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: 4.53%
H: 7.71%
C: 0.0%
xtx101 trial therapeutics
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
Published: 2023-11-09 (Crawled : 21:00) - globenewswire.com
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: 9.38%
H: 0.46%
C: -18.29%
business pipeline therapeutics financial results
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 15.75%
C: -4.0%
xtx202 tumors
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline
Published: 2023-10-31 (Crawled : 15:00) - biospace.com/
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: -0.48%
H: 6.11%
C: 4.78%
conference review pipeline
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
Published: 2023-10-31 (Crawled : 13:00) - globenewswire.com
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: -0.48%
H: 6.11%
C: 4.78%
xtx202 conference review meeting
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Published: 2023-09-27 (Crawled : 21:00) - globenewswire.com
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: 4.27%
H: 1.36%
C: -1.82%
immunotherapy meeting therapeutics
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
Published: 2023-09-05 (Crawled : 12:30) - globenewswire.com
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: -3.79%
H: 3.94%
C: 0.0%
medical therapeutics
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
Published: 2023-09-05 (Crawled : 12:00) - globenewswire.com
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: -3.79%
H: 3.94%
C: 0.0%
MS | News 0 d | $90.26 0.2% 0.0% 6.7M
|
Finance
|
| O: 0.01%
H: 0.0%
C: 0.0%
conference global therapeutics
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
Published: 2023-08-14 (Crawled : 12:00) - globenewswire.com
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 3.57%
C: 2.14%
business pipeline therapeutics financial results
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
Published: 2023-08-03 (Crawled : 20:00) - globenewswire.com
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: 1.45%
H: 2.15%
C: 2.15%
PPRUF | News | $361.9 37.56% 4.3K
|
Consumer Non-Durables
|
| O: -1.74%
H: 2.24%
C: 2.16%
PPRUY | News | $36.03 -0.11% 330K
|
Manufacturing
|
| O: 1.24%
H: 0.79%
C: -0.84%
therapeutics
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
Published: 2023-05-25 (Crawled : 21:00) - globenewswire.com
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: 3.58%
H: 0.0%
C: -3.77%
xtx101 tumors trial therapeutics
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
Published: 2023-05-09 (Crawled : 11:00) - globenewswire.com
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: -1.98%
H: 4.2%
C: 4.2%
business pipeline therapeutics financial results
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-04-03 (Crawled : 20:00) - globenewswire.com
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: 1.97%
H: 3.06%
C: 3.06%
nasdaq grant therapeutics
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.